













26. Parziale N, Kovacs SC, Thomas CB, et al. Rituximab and Mycophenolate Combination Therapy in Refractory Dermatomyositis With Multiple Autoimmune Disorders. *J Clin Neuromuscul Dis.* 2011; 13: 63-7.
27. Joshi N, Nautiyal A, Davies PG. Successful Use of Rituximab in Recalcitrant Skin Predominant Dermatomyositis. *J Clin Rheumatol.* 2011; 17: 111-2.
28. Aggarwal R, Bandos A, Reed AM, et al. Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. *Arthritis Rheumatol.* 2014; 66: 740-9.
29. Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. *Rheumatology.* 2016; 55: 1318-24.
30. Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. *Rheumatology.* 2015; 54: 1420-8.
31. Marie I, Dominique S, Janvresse A, et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. *Respir Med.* 2012; 106: 581-7.
32. Dasa O, Ruzieh M, Oraibi O. Successful Treatment of Life-Threatening Interstitial Lung Disease Secondary to Antisynthetase Syndrome Using Rituximab. *Ann Rheum Dis.* 2016; 23: e639-45.
33. Vandenbroucke E, Grutter JC, Altenburg J, et al. Rituximab in life-threatening antisynthetase syndrome. *Rheumatol Int.* 2009; 29: 1499-502.
34. Furlan A, Borsini C, Ruffatti A, et al. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report. *Joint Bone Spine Rev Rheum.* 2008; 75: 366-7.
35. Nalotto L, Iaccarino L, Zen M, et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. *Immunol Res.* 2013; 56: 362-70.
36. Luca NJC, Atkinson A, Hawkins C, et al. Anti-signal Recognition Particle-positive Juvenile Polymyositis Successfully Treated with Rituximab. *J Rheumatol.* 2012; 39: 1483-5.
37. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: A case series. *Arthritis Care Res (Hoboken).* 2010; 62: 1328-34.
38. Pinal-Fernandez I, Parks C, Werner JL, et al. Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. *Arthritis Care Res (Hoboken).* 2017; 69: 263-70.
39. Basnayake U, Cash K, Blumbergs P, et al. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. *Clin Rheumatol.* 2015; 34: 371-7.
40. Prajira RMR, de Carvalho J. Glucocorticoid-induced myopathy. *Joint Bone Spine Rev Rheum.* 2011; 78: 41-4.
41. Unger L, Kampf S, Luthke K, et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. *Rheumatology.* 2014; 53: 1630-8.
42. Nalotto L, Iaccarino L, Zen M, et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. *Immunol Res.* 2013; 56: 362-70.
43. Belhassen-Garcia M, Rabano-Gutierrez A, Velasco-Tirado V, et al. Atypical Progressive Multifocal Leukoencephalopathy in a Patient with Antisynthetase Syndrome. *Intern Med.* 2015; 54: 519-24.
44. Marie I, Guegan-Massardier E, Levesque H. Progressive multifocal leukoencephalopathy in refractory polymyositis treated with rituximab. *Eur J Intern Med.* 2011; 22: e13-4.